Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Case Study: Benefits of Post-Acute Nursing Facility vs. Home Care

When a patient is released from the hospital, patient advocates often believe their best chance for recovery and avoidance of readmission is in-home medical care and rehabilitation versus admittance into a skilled nursing facility (SNF). During hospitalization, however, it’s challenging to envision the in-home post-acute care needs for each unique patient. Thus, it’s not a…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

When a patient is released from the hospital, patient advocates often believe their best chance for recovery and avoidance of readmission is in-home medical care and rehabilitation versus admittance into a skilled nursing facility (SNF). During hospitalization, however, it’s challenging to envision the in-home post-acute care needs for each unique patient. Thus, it’s not a simple narrative on which option will best facilitate a quick and full recovery.

The Determining Factors

To gain better insight, a study by Penn State University Leonard Davis Institute of Health Economics (LDI) looked to determine the differences in 30-day readmission rates, 30-day mortality rates, functional outcomes, and Medicare costs between those patients discharged to home health and those to an SNF. The assessment factors were unique in that the research used a large data set (17 million Medicare beneficiary hospitalizations), controls for patient characteristics across care settings, and included patients with many different ailments.

The Findings

During 2010 and 2016, of the more than 17 million discharges considered in the study, over 40% of the patients received some type of post-acute services—39% were released into a home care setting and 61% to an SNF. While those discharged to home rehab had a 5.6% higher readmission rate at 30 days than those in the SNF category, it is assumed that the 24-hour monitored care and higher level of treatment provided by an SNF reduced the likelihood of post-acute complications. However, the slightly higher readmission rates of home-recovery patients were not attributed to life-threatening symptoms such as respiratory failure but were based on potential cautionary reasons at the caregiver’s or patient’s discretion.

When it comes to costs, the average savings per patient discharged to in-home care was $5,385 less than patients admitted to SNFs. Further, the total Medicare payment within the first 60 days following hospitalization was also less for the home health care group, with a savings of $4,514 per patient. Interestingly enough, though, the study found no difference in improved patient functionality from the home health setting versus a SNF, nor were their disparities in mortality rates between each group. While the study correlates fewer readmissions with SNFs, these facilities did incur significantly increased Medicare spending per patient.

Clinicians must be able to balance the benefits of both settings to ensure the best outcome for their patients. Additional research to better understand which patient profiles would most benefit from SNF care or may be less likely to be readmitted after discharge to home health care could provide vital insight for caregivers and hospitals alike.

Help for Home Caretakers

When a patient is released to in-home care, their family or friends are often the ones tasked with helping in their recovery. This care typically involves changing dressings, managing medications, and the operation of fundamental medical equipment. AliMed is committed to providing patients and caregivers with a wide selection of quality at-home specialty healthcare products designed to improve quality of life and promote safer, easier, and more independent living. Click here to learn more.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended AstraZeneca and Daiichi Sankyo’s Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly is investing $6.5 billion in a Houston manufacturing facility set to open around 2030, primarily to scale production of Foundayo, its oral GLP-1 treatment. The project signals a broader shift in U.S. pharmaceutical manufacturing reshoring and underscores the supply chain challenge of forecasting demand and building capacity years in advance for breakthrough therapeutics.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain: Lilly's CEO noted that one-third of new GLP-1 pill patients are now choosing Foundayo, illustrating fast-moving market share shifts that complicate production planning years in advance
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

Waiting for perfectly clean data is stalling healthcare AI, not protecting it

Healthcare organizations often delay AI initiatives waiting for perfectly clean data, but this assumption no longer holds: reliable subsets and synthetic data allow projects to start now while data work continues in parallel. Success requires starting with business outcomes rather than technology capabilities, and embedding governance in product strategy before implementation, not after.

  • 01Waiting for 100% clean data is effectively a decision never to start; hospital AI projects can begin on reliable data subsets while quality work continues in parallel.
  • 02Frame AI decisions around business outcomes (revenue growth, cost reduction, competitive advantage, new products, or ecosystem influence) rather than asking what AI can do.
  • 03Governance should be part of product strategy before design or purchase, especially as agentic AI takes actions—such as handling many revenue-cycle denials—while routing the rest to humans.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512